Summary of Innoviva (INVA) 2025 Conference Call Company Overview - **Company**: Innoviva (INVA) - **Industry**: Healthcare, specifically focusing on respiratory, infectious disease, and critical care therapeutics - **Key Products**: ANORO® ELLIPTA®, RELVAR®/BREO® ELLIPTA®, GIAPREZA®, ZEVTERA®, zoliflodacin Core Business Segments 1. **Royalties**: - Generates approximately **$250 million** in annual revenue, considered resilient and durable [3][26] - Royalties stem from respiratory products co-developed with Glaxo Group Limited (GSK) [2] 2. **Innoviva Specialty Therapeutics (IST)**: - Focuses on infectious disease and critical care, generating over **$100 million** in revenue last year, with a growth rate of **50%** [4][6] - Recent product launches include ZEVTERA® and upcoming zoliflodacin, with aspirations for revenues exceeding **$500 million** in the U.S. [7][20] 3. **Strategic Healthcare Assets**: - Portfolio valued at just under **$500 million**, includes stakes in companies with disruptive potential [4] Growth Potential and Strategy - The IST business is designed for differentiated assets in high unmet medical needs, with plans for both organic and inorganic growth [8][10] - The company is exploring additional investments outside the IST business, particularly in strategic healthcare assets [11] Product Insights - **GIAPREZA®**: - Rapid revenue growth post-relaunch, with potential tailwinds from updated sepsis guidelines [13] - **ZEVTERA®**: - Launched in July, approved for three indications, with positive initial reception [17] - **zoliflodacin**: - Targets uncomplicated gonorrhea, addressing a significant unmet need with a once-dosed oral option [19][20] - Anticipated PDUFA date in December, with potential for telehealth prescriptions [21] Market Dynamics - Drug resistance is a global issue, with Innoviva's products positioned to address rising resistance rates [15][16] - The company is aware of competitive pressures but believes in the resilience of its existing products [29] Strategic Investments - Innoviva has extended credit to Armata, a bacteriophage company, which has shown promising clinical results [30][31] - Investment in Sindeo, focused on neuroscience and depression, with potential for significant value creation [36] Financial Position - Innoviva is well-capitalized with approximately **$400 million** in cash and generating cash flow, allowing for strategic capital deployment [38] Conclusion - Innoviva is positioned for growth through its diversified business segments, innovative product pipeline, and strategic investments, while maintaining a strong financial foundation to navigate market volatility [39]

Innoviva (INVA) FY 2025 Conference September 03, 2025 08:45 AM ET Company ParticipantsJaison Ellis - MD - Healthcare Investment BankingAustin Hackett - VP - Business DevelopmentJaison EllisHello everyone. Thanks for joining the Innoviva fireside chat. My name is Jason Ellis. I'm a Managing Director in our biopharma investment banking group, and I have here with me Austin Hackett, who is the Vice President of Business Development and Investor Relations at Innoviva. Great to have you with us.Austin HackettTha ...

Innoviva (INVA) FY 2025 Conference September 03, 2025 08:45 AM ET Speaker0Hello everyone. Thanks for joining the Innoviva fireside chat. My name is Jason Ellis. I'm a Managing Director in our biopharma investment banking group, and I have here with me Austin Hackett, who is the Vice President of Business Development and Investor Relations at Innoviva. Great to have you with us.Speaker1Thanks, Jason. Very happy to be here, and thanks for having us.Speaker0Excellent. We'll just start off by going through some ...

Innoviva (INVA) FY 2025 Conference September 03, 2025 08:45 AM ET Speaker0Hello everyone. Thanks for joining the Innoviva fireside chat. My name is Jason Ellis. I'm a Managing Director in our biopharma investment banking group, and I have here with me Austin Hackett, who is the Vice President of Business Development and Investor Relations at Innoviva. Great to have you with us.Speaker1Thanks, Jason. Very happy to be here, and thanks for having us.Speaker0Excellent. We'll just start off by going through some ...